

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2



EPAS ID: PAT7341698

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
DALIAN UNIVERSITY OF TECHNOLOGY	05/18/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BEIJING BIOSTAR PHARMACEUTICALS CO., LTD.
<b>Street Address:</b>	SUITE 310, BUILDING 3, NO., 88 KECHUANG 6TH STREET
<b>City:</b>	BEIJING
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	101111
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	12896144
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(610)407-0701
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6104070700
<b>Email:</b>	maclemmons@ratnerprestia.com
<b>Correspondent Name:</b>	RATNERPRESTIA
<b>Address Line 1:</b>	2200 RENAISSANCE BOULEVARD
<b>Address Line 2:</b>	SUITE 350
<b>Address Line 4:</b>	KING OF PRUSSIA, PENNSYLVANIA 19406
<b>ATTORNEY DOCKET NUMBER:</b>	LTI-100US
<b>NAME OF SUBMITTER:</b>	LING ZHONG, REG. NO. 48,290
<b>SIGNATURE:</b>	/Ling Zhong/
<b>DATE SIGNED:</b>	05/20/2022
<b>Total Attachments: 2</b>	
source=LTI-100US_Assignment#page1.tif	
source=LTI-100US_Assignment#page2.tif	

<b>ASSIGNMENT - Patent Application</b>		Docket Number: <b><u>LTI-100US</u></b>
Whereas, the Assignor, comprising the following named inventors:		
ASSIGNOR(s)/ INVENTOR(s)	1. <b>Dalian University of Technology</b>	2.
	3.	4.
	5.	6.
made an invention entitled: <b><u>FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF</u></b>		
for which an application for Letters Patent of the United States (the Application): <i>(Select one of the following):</i> <input type="checkbox"/> is submitted concurrently herewith <input checked="" type="checkbox"/> was filed in the U.S. Patent and Trademark Office on <b><u>October 1, 2010</u></b> , as U.S. Patent Application No.: <b><u>12/896,144</u></b>		
ASSIGNEE (Full Name and Address)	<b>Beijing Biostar Pharmaceuticals Co., Ltd. Suite 310, Building 3, No., 88 Kechuang 6th Street Beijing 101111, China</b>	
<p>is desirous of acquiring the entire interest in and to said invention and the Letters Patent to be obtained therefor,</p> <p>Now, therefore, in consideration of the payment by Assignee to Assignor of a sum corresponding to One Dollar (\$1.00), and for other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor, intending to be legally bound, hereby sells, assigns and transfers to Assignee, its successors and assigns, the full and exclusive right, title and interest in and to said invention, all applications for Letters Patent for said invention, including the Application, all divisions, continuations, and continuations-in-part thereof and non-provisional applications claiming priority thereto, all rights to claim priority based thereon, and all Letters Patent, including reissues, to be obtained therefor, including any and all foreign patent rights in this invention corresponding thereto and authorizes Assignee to file such applications for Letters Patent in the United States and any and all other countries.</p> <p>Assignor hereby warrants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.</p> <p>Assignor agrees it shall be legally bound, upon request of the Assignee or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the Assignor has knowledge or possession, relating to the making and practice of said invention, to testify in any legal proceeding relating thereto, to execute all instruments proper to patent the invention in the United States of America and foreign countries in the name of the Assignee, and to execute all instruments proper to carry out the intent of this instrument. Assignor also agrees that it will not engage, participate, or take part in any action conflicting with this Assignment, including but not limited to challenging the validity or patentability or enforceability of any patent rights relating to this invention or assisting others with such a challenge.</p> <p>If any provision in this Assignment is held invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</p> <p>If the invention requires a biological deposit, Assignor also grants to Assignee such control over any deposit made by Assignor as may be necessary to the validity of the patent rights assigned herein.</p> <p>Assignor authorizes Assignee's attorney to insert the serial number and filing date of the aforesaid application for United States Letters Patent and/or the Attorney Docket or file designation for this application if not identified above.</p> <p>If the Assignor includes more than one individual, these obligations shall apply to these individuals both individually and collectively.</p>		

**ASSIGNMENT - Patent Application**Docket Number: **LTI-100US**

In witness whereof, this Assignment is executed on the day indicated below.

	Typed or Printed Name	Signature	Date
SIGNATURE	1. <b>Dalian University of Technology</b>		18/05/22
			18/05/22
		* Witness to Assignor # 1	
	2.		
		* Witness to Assignor # 2	
	3.		
		* Witness to Assignor # 3	
	4.		
		* Witness to Assignor # 4	
5.			
	* Witness to Assignor # 5		
6.			
	* Witness to assignor # 6		

Application for United States Letters Patent:

Application No.: **12/896,144**Filing Date: **October 1, 2010**Attorney Docket Number: **LTI-100US**Total Number of Assignment Pages **2**

\* Witness signature recommended, mandatory for some countries